Latest News on RGNX

Financial News Based On Company


Advertisement
Advertisement

RGNX: Wet AMD pivotal data approach as retinal programs advance toward commercial and clinical milestones

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4574527:0-rgnx-wet-amd-pivotal-data-approach-as-retinal-programs-advance-toward-commercial-and-clinical-milestones/
REGENXBIO (RGNX) is nearing pivotal results for its RGX-314 wet AMD treatment, expected by year-end, with a focus on reducing treatment burden. The company is also preparing for commercialization by building a surgeon network and advancing other retinal programs like the NAAVIGATE DR study and RGX-202, which seeks accelerated approval based on functional and safety data. This information stems from REGENXBIO's presentation at the Stifel 2026 Healthcare Conference.

News Flash: Analysts Just Made A Notable Upgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) Forecasts

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgnx/regenxbio/news/news-flash-analysts-just-made-a-notable-upgrade-to-their-reg
Analysts have significantly upgraded their statutory forecasts for REGENXBIO Inc. (NASDAQ:RGNX) for the next year, notably increasing revenue estimates to US$250m for 2027 and reducing anticipated losses to US$2.38 per share. Despite these positive revisions, the price target remains unchanged at US$24.00, suggesting the latest estimates haven't impacted long-term valuation views. The company is expected to grow faster than its competitors, with revenue growth accelerating to 48% annually by the end of 2027.

Form SCHEDULE 13G REGENXBIO Inc. Filed by: STATE STREET CORP

https://www.streetinsider.com/SEC+Filings/Form+SCHEDULE+13G+REGENXBIO+Inc.+Filed+by%3A+STATE+STREET+CORP/27320366.html
State Street Corporation has filed a Schedule 13G form indicating its beneficial ownership in REGENXBIO Inc. The filing shows State Street Corporation owns 3,153,366 shares, representing 4.8% of the class of common stock as of September 30, 2026. This ownership includes shared voting power over 3,081,970 shares and shared dispositive power over 3,153,366 shares.

A 3.15 million-share REGENXBIO (RGNX) stake is reported by State Street.

https://www.stocktitan.net/sec-filings/RGNX/schedule-13g-regenxbio-inc-passive-investment-disclosure-5-299da564c6fe.html
State Street Corporation has reported a beneficial ownership of 3,153,366 shares, or a 4.8% passive stake, in REGENXBIO Inc. (RGNX) as of September 30, 2026. This disclosure was made in a SCHEDULE 13G SEC filing. The report details shared voting power over 3,081,970 shares and shared dispositive power over 3,153,366 shares, with several State Street subsidiaries listed as acquirers of the securities.

Mizuho cuts Regenxbio stock price target on pipeline timing By Investing.com

https://in.investing.com/news/stock-market-news/mizuho-cuts-regenxbio-stock-price-target-on-pipeline-timing-93CH-5686412
Mizuho has reduced its price target for Regenxbio Inc. (NASDAQ:RGNX) to $18 from $19, while maintaining an Outperform rating, citing pipeline timing despite the company beating revenue expectations and showing lower operating expenses in its Q3 results. Regenxbio reaffirmed key milestones for its late-stage programs, including Phase 3 data for suravec in Q4 2026 and a BLA submission for RGX-202 in Q1 2027. Despite a recent revenue miss, the company increased its cash balance to $251 million, projecting it will sustain operations into late 2027.
Advertisement

Regenxbio Inc (RGNX) (Q3 2026) Earnings Call Highlights: Dual Gene Therapy Catalysts Near ...

https://ca.finance.yahoo.com/news/regenxbio-inc-rgnx-q3-2026-073333570.html
Regenxbio Inc (RGNX) is nearing significant regulatory milestones with potential approvals for sura-vec in wet AMD and RGX-202 for Duchenne. The company reported a strong cash position and outlined its strategy for BLA submissions and commercialization, despite facing competition and regulatory uncertainties. Key differentiators for its therapies include subretinal immune privilege for sura-vec and a robust manufacturing process and immune suppression regimen for RGX-202.

REGENXBIO Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:a92e430ce094b:0-regenxbio-q3-earnings-call-highlights/
REGENXBIO is nearing pivotal trial results for its wet age-related macular degeneration (wet AMD) gene therapy, sura-vec, with top-line results expected this quarter from two studies. The company also plans to submit a biologics license application for its Duchenne muscular dystrophy treatment, RGX-202, in Q1 2027, aiming for accelerated approval. REGENXBIO ended Q3 with $251 million in cash, projecting a cash runway into late Q4 2027.

Mizuho cuts Regenxbio stock price target on pipeline timing

https://www.investing.com/news/analyst-ratings/mizuho-cuts-regenxbio-stock-price-target-on-pipeline-timing-93CH-5007331
Mizuho lowered its price target for Regenxbio Inc. to $18 from $19, while maintaining an Outperform rating, despite the biotechnology company beating third-quarter revenue expectations and reporting lower operating expenses. The adjustment reflects pipeline timing, as Regenxbio reaffirmed key milestones for its late-stage programs, including Phase 3 data for suravec in Q4 2026 and a BLA submission for RGX-202 in Q1 2027. Despite the stock trading down nearly 49% year-to-date, InvestingPro analysis suggests it is currently undervalued.

Mizuho cuts Regenxbio stock price target on pipeline timing By Investing.com

https://ca.investing.com/news/stock-market-news/mizuho-cuts-regenxbio-stock-price-target-on-pipeline-timing-93CH-4938351
Mizuho has lowered its price target for Regenxbio Inc. (NASDAQ:RGNX) to $18 from $19, while maintaining an Outperform rating. This adjustment comes despite the company beating revenue expectations and showing lower operating expenses in its third-quarter results. Regenxbio also reaffirmed key milestones for its late-stage pipeline, including Phase 3 data for suravec in Q4 2026 and a BLA submission for RGX-202 in Q1 2027.

Regenxbio Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62919757/regenxbio-q3-2026-earnings-call-transcript
Regenxbio reported a strong cash position of $251 million in Q3 2026, driven by a $100 million payment from AbbVie and a public offering. The company is nearing regulatory submissions for Suravec (wet AMD, diabetic retinopathy) in 2027 and RGX202 (Duchenne muscular dystrophy) in Q1 2027, with anticipated commercial launches in late 2027. Regenxbio emphasized Suravec's potential for broad regulatory approval and RGX202's unique microdystrophin construct and safety profile as key differentiators.
Advertisement

REGENXBIO Inc. (RGNX) Reports $9.2M Revenue, Cash Runway Into Late Q4 2027

https://www.tradingview.com/news/tradingview:6aa8ec556a2b3:0-regenxbio-inc-rgnx-reports-9-2m-revenue-cash-runway-into-late-q4-2027/
REGENXBIO Inc. (RGNX) reported Q3 2026 revenue of $9.2M, a significant drop from $29.7M in Q3 2025, primarily due to lower ZOLGENSMA royalties. Despite a net loss of $40.7M, an improvement from $61.9M year-over-year partly due to a $38.0M litigation settlement, the company expects its current cash balance and October receipts to fund operations into late Q4 2027. The company anticipates upcoming catalysts including pivotal sura-vec data this quarter and an RGX-202 BLA submission early next year.

Regenxbio Inc earnings beat by $0.62, revenue fell short of estimates

https://uk.investing.com/news/earnings/regenxbio-inc-earnings-beat-by-062-revenue-fell-short-of-estimates-4960670
Regenxbio Inc (NASDAQ: RGNX) reported third-quarter earnings per share (EPS) of $-0.62, significantly beating analyst estimates. However, the company's revenue of $9.16 million fell short of the consensus estimate of $14.87 million. The stock has seen a decline over the last three and twelve months, with its financial health rated as "fair performance" by InvestingPro.

REGENXBIO (RGNX) CTO Malzahn received 27,777 shares

https://www.quantisnow.com/insight/chief-technology-officer-malzahn-craig-was-granted-27777-shares-increasing-6770144
Craig Malzahn, Chief Technology Officer at REGENXBIO Inc. (RGNX), reported receiving 27,777 restricted stock unit (RSU) shares on November 1, 2026, increasing his direct holdings to 109,737 shares. These RSU shares will vest in one-third increments on November 1, 2027, 2028, and 2029, contingent on his continuous service to the company. This transaction is categorized as a grant or award under an exempt employee plan, with no cost incurred by Malzahn.

Medical chief Steve Pakola receives a 34,722-share stock award at REGENXBIO (RGNX).

https://www.stocktitan.net/sec-filings/RGNX/form-4-regenxbio-inc-insider-trading-activity-3f1e0d16de9c.html
REGENXBIO Inc.'s Chief Medical Officer, Steve Pakola, was granted a time-based restricted stock unit award of 34,722 shares on November 1, 2026. One-third of these shares will vest annually on November 1, 2027, 2028, and 2029, contingent on his continuous service to the company. Following this award, Pakola's direct holdings in REGENXBIO total 240,263 shares.

A live New York chat with REGENXBIO is set for Nov. 11

https://www.stocktitan.net/news/RGNX/regenxbio-to-participate-in-stifel-2026-healthcare-y01ifmgylx6s.html
REGENXBIO (Nasdaq: RGNX) announced its participation in the Stifel 2026 Healthcare Conference on November 11, 2026, in New York. The company's fireside chat is scheduled for 9:20 a.m. ET and will be accessible via a live webcast on its Investors section, with an archived replay available for approximately 30 days. REGENXBIO, a biotechnology company founded in 2009, focuses on advancing gene therapy for rare and retinal diseases.
Advertisement

(RGNX) and the Role of Price-Sensitive Allocations

https://news.stocktradersdaily.com/news_release/21/RGNX_and_the_Role_of_Price-Sensitive_Allocations_110326074402_1793709842.html
This article provides an AI-generated analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting near-term strong sentiment challenging persistent mid and long-term weakness. It details institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for the stock.

REGENXBIO INC. : MIZUHO CUTS TARGET PRICE TO $19 FROM $22

https://www.moomoo.com/news/flash/1002809309/regenxbio-inc-mizuho-cuts-target-price-to-19-from-22
Mizuho has adjusted its target price for REGENXBIO INC. (RGNX) shares, reducing it from $22 to $19. This revision suggests a change in the firm's outlook on the company's future stock performance.

REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights

https://www.moomoo.com/news/post/1002814495/regenxbio-to-host-conference-call-on-november-5-to-discuss
REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on November 5, 2026, to discuss its third quarter 2026 financial results and provide an operational update. The call will also be webcast live, with a replay available for 30 days.

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?

https://ca.finance.yahoo.com/news/regenxbio-rgnx-expected-beat-earnings-130005452.html
Regenxbio (RGNX) is projected to experience a year-over-year decline in earnings and revenues for the quarter ended September 2026, though it is still expected to beat earnings estimates. The company's Zacks Earnings ESP of +6.53% combined with a Zacks Rank #2 suggests a high probability of an earnings beat. Acadia Pharmaceuticals (ACAD), another industry player, is also anticipated to beat its EPS estimates.

A biotech company will discuss its third-quarter results and operations at 8 a.m. ET on Nov. 5.

https://www.stocktitan.net/news/RGNX/regenxbio-to-host-conference-call-on-november-5-to-discuss-third-p9dzyvcdhqoo.html
REGENXBIO Inc. (Nasdaq: RGNX) announced it will host a conference call on November 5, 2026, at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2026, and operational highlights. The call will also be available via a webcast replay on the company's investor website. REGENXBIO is a biotechnology company focused on advancing gene therapy treatments for rare and retinal diseases.
Advertisement

REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights

https://www.tradingview.com/news/prnewswire:eebaab0890583:0-regenxbio-to-host-conference-call-on-november-5-to-discuss-third-quarter-2026-financial-results-and-operational-highlights/
REGENXBIO Inc. (Nasdaq: RGNX) announced it will host a conference call on Thursday, November 5, 2026, at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2026, and operational highlights. The biotechnology company, focused on AAV gene therapy, is advancing treatments for rare and retinal diseases, including Duchenne, MPS II, MPS I, wet AMD, and diabetic retinopathy. A replay of the webcast will be available on the company's investor website.

REGENXBIO stock: Bank of America sets USD 15.00 target for REGENXBIO stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/regenxbio-stock-bank-of-america-sets-usd-15-00-target-for-regenxbio-stock/70402085
Bank of America Securities has set a USD 15.00 price target for REGENXBIO (RGNX) stock, maintaining a Buy rating, while Mizuho initiated coverage with a higher USD 22.00 target. The company reported a significant increase in second-quarter 2026 revenue to USD 108.02 million and anticipates topline pivotal data for its sura-vec program in wet AMD in the fourth quarter of 2026. REGENXBIO's stock was trading at USD 6.68, well below both analyst targets, with a market capitalization of USD 441.0 million.

REGENXBIO Inc. Estimates – NASDAQ:RGNX

https://www.tradingview.com/symbols/NASDAQ-RGNX/financials-estimates/
This page on TradingView provides an overview of REGENXBIO Inc. (RGNX) financial data and analyst estimates. Users can explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates. The platform also visualizes trends over time, making it a resource for investors to research the company's financial performance.

Morgan Stanley Initiates Regenxbio(RGNX.US) With Buy Rating, Announces Target Price $18

https://www.moomoo.com/news/post/1001870545/morgan-stanley-initiates-regenxbio-rgnxus-with-buy-rating-announces-target
Morgan Stanley has initiated coverage of Regenxbio (RGNX.US) with a "Buy" rating. The investment bank has set a target price of $18 for the stock. This initiation suggests a positive outlook from Morgan Stanley on Regenxbio's future performance.

REGENXBIO schedules October 20 event: REGENXBIO stock gains 8.87 percent

https://www.ad-hoc-news.de/boerse/news/nebenwerte/regenxbio-schedules-october-20-event-regenxbio-stock-gains-8-87-percent/70377039
REGENXBIO (RGNX) held an investor event on October 20, 2026, focusing on surabgene lomparvovec for wet age-related macular degeneration, which caused its stock to gain 8.87 percent, trading at EUR 6.70 at Lang & Schwarz. The company also reported strong second-quarter 2026 revenues of USD 108.02 million, exceeding consensus estimates, and its stock traded 40.70 percent above its 52-week low. Analysts have initiated coverage with an Outperform rating and a USD 22.00 price target, significantly above the current Nasdaq price.
Advertisement

REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy

https://www.tradingview.com/news/marketbeat:dfdfbb8df094b:0-regenxbio-eyes-q4-pivotal-readout-for-one-time-wet-amd-gene-therapy/
REGENXBIO (RGNX) is preparing for a Q4 pivotal readout for its one-time subretinal gene therapy, sura-vec, for wet age-related macular degeneration (wet AMD). The company expects top-line results from its ATMOSPHERE and ASCENT studies, which could support a 2027 regulatory submission. Sura-vec aims to reduce the treatment burden of frequent anti-VEGF injections for the broad wet AMD patient population, with encouraging earlier-stage data showing maintained vision and reduced injection needs.

Barclays keeps USD 12.00 target for REGENXBIO stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/barclays-keeps-usd-12-00-target-for-regenxbio-stock/70350727
Barclays has maintained a Hold rating and a $12.00 price target for REGENXBIO (RGNX) stock. This target is 73.16% above the Nasdaq closing price of $6.93 on October 16, 2026. The company reported second-quarter 2026 revenue of $108.02 million, surpassing the consensus estimate of $97.63 million, and adjusted earnings of $0.43 per share against an estimate of $0.08.

Form 8-K REGENXBIO Inc. For: Oct 14

https://www.streetinsider.com/SEC+Filings/Form+8-K+REGENXBIO+Inc.+For%3A+Oct+14/27195554.html
REGENXBIO Inc. filed a Form 8-K on October 14, 2026, announcing the resignation of Kenneth T. Mills from its board of directors, effective October 21, 2026. Mills resigned to focus on his new role as CEO of another company. Following his departure, the board appointed George Migausky as Chairman, and Daniel Tassé stepped down as Lead Independent Director but remains a board member.

Mizuho sets USD 22.00 target for REGENXBIO stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/mizuho-sets-usd-22-00-target-for-regenxbio-stock/70331974
Mizuho has set a USD 22.00 price target for REGENXBIO (RGNX) stock, significantly higher than its current trading price. The company is preparing for an investor event on October 20, 2026, to discuss its wet age-related macular degeneration program. REGENXBIO reported a market capitalization of USD 463.5 million and positive earnings in the second quarter of 2026.

Price-Driven Insight from (RGNX) for Rule-Based Strategy

https://news.stocktradersdaily.com/news_release/101/Price-Driven_Insight_from_RGNX_for_Rule-Based_Strategy_101326103802_1791945482.html
This article provides a price-driven insight for Regenxbio Inc. (NASDAQ: RGNX), highlighting stable neutral readings in shorter horizons which could signal an easing of a long-term weak bias. It details exceptional risk-reward setups, specifically a short setup targeting a 34.2% downside, and outlines three distinct AI-generated trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored for different risk profiles. The analysis also includes multi-timeframe signal analysis with identified support and resistance levels.
Advertisement

JPMorgan reports a passive stake above 5% in REGENXBIO (RGNX).

https://www.stocktitan.net/sec-filings/RGNX/schedule-13g-regenxbio-inc-passive-investment-disclosure-5-63b0f1a2a0ad.html
JPMorgan Chase & Co. has reported a passive beneficial ownership stake of 5.3% in REGENXBIO Inc. (RGNX), amounting to 3,560,915 shares, as of September 30, 2026. The filing indicates JPMorgan holds sole voting power over 3,324,340 shares and sole dispositive power over all 3,560,915 shares. This disclosure was made via a SCHEDULE 13G SEC filing, signifying a passive investment.

Form SCHEDULE 13G REGENXBIO Inc. Filed by: JPMORGAN CHASE & CO

https://www.streetinsider.com/SEC+Filings/Form+SCHEDULE+13G+REGENXBIO+Inc.+Filed+by%3A+JPMORGAN+CHASE+%26amp%3B+CO/27180399.html
JPMorgan Chase & Co. filed a Schedule 13G with the SEC, reporting beneficial ownership of 3,560,915 shares of REGENXBIO Inc. common stock, representing 5.3% of the class. The filing indicates JPMorgan Chase & Co. has sole voting power over 3,324,340 shares and sole dispositive power over 3,560,915 shares. This filing is made in the ordinary course of business and not for the purpose of changing or influencing the control of REGENXBIO Inc.

Barclays Maintains Regenxbio(RGNX.US) With Hold Rating, Maintains Target Price $12

https://www.moomoo.com/news/post/1001022240/barclays-maintains-regenxbio-rgnxus-with-hold-rating-maintains-target-price
Barclays has reiterated its Hold rating on Regenxbio (RGNX.US) and maintained its target price at $12. This indicates the analyst's view that the stock is expected to perform in line with the broader market.

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

https://www.marketscreener.com/news/regenxbio-to-host-investor-event-highlighting-surabgene-lomparvovec-sura-vec-in-wet-amd-on-october-ce785ddcd181f42d
REGENXBIO Inc. (Nasdaq: RGNX) announced an investor event on October 20, 2026, to discuss its surabgene lomparvovec (sura-vec) clinical program for wet age-related macular degeneration (wet AMD). The event will provide a clinical overview, expert perspectives on the treatment landscape, and insights into the ATMOSPHERE® and ASCENT® pivotal trials, ahead of topline pivotal data expected in Q4 2026. The company is dedicated to advancing gene therapy for rare and retinal diseases, including partnerships with Nippon Shinyaku and AbbVie.

REGENXBIO’s diabetic eye gene therapy reaches three-year mark

https://longevity.technology/news/regenxbios-diabetic-eye-gene-therapy-reaches-three-year-mark/
REGENXBIO presented three-year follow-up data from its Phase II ALTITUDE trial for surabgene lomparvovec (sura-vec), a gene therapy for non-proliferative diabetic retinopathy. The data showed that 60% of patients receiving Dose Level 3 improved by two or more steps on the Diabetic Retinopathy Severity Scale without needing additional treatment. This early, small-scale trial suggests sura-vec could be a one-time treatment, offering a significant advantage over current repetitive injection therapies for diabetic eye disease.
Advertisement

Mizuho initiates Regenxbio stock coverage with outperform rating

https://www.investing.com/news/analyst-ratings/mizuho-initiates-regenxbio-stock-coverage-with-outperform-rating-93CH-4931341
Mizuho has initiated coverage on Regenxbio Inc. (NASDAQ:RGNX) with an outperform rating and a $22.00 price target, citing the company's gene therapy pipeline for diseases with high unmet needs. The firm highlights two lead assets, RGX-202 for Duchenne muscular dystrophy and ABBV-RGX-314 for wet age-related macular degeneration and diabetic retinopathy, as key drivers for its positive outlook. Despite investor debates, Mizuho believes the stock is undervalued and offers substantial upside potential.

Mizuho initiates Regenxbio stock coverage with outperform rating By Investing.com

https://ng.investing.com/news/stock-market-news/mizuho-initiates-regenxbio-stock-coverage-with-outperform-rating-93CH-2721070
Mizuho has initiated coverage on Regenxbio Inc. (NASDAQ:RGNX) with an outperform rating and a price target of $22.00, representing a significant upside from its current stock price. The positive outlook is based on Regenxbio's gene therapy pipeline, particularly RGX-202 for Duchenne muscular dystrophy and ABBV-RGX-314 for eye diseases. Despite investor debates around gene therapies, Mizuho's robust financial model supports its optimistic view, with InvestingPro analysis also suggesting the stock is undervalued.

Mizuho Initiates Regenxbio (RGNX) Coverage with Outperform Ratin

https://www.gurufocus.com/news/9109761/mizuho-initiates-regenxbio-rgnx-coverage-with-outperform-rating-22-price-target
Mizuho has initiated coverage on Regenxbio (RGNX) with an Outperform rating and a $22 price target, citing optimism around the company's gene therapies for Duchenne muscular dystrophy and retinal diseases, particularly the upcoming wet AMD data as a key catalyst. Despite the positive outlook, the company faces significant financial challenges, including ongoing losses, negative cash flow, and low financial strength, as reflected by its GF Score of 60/100 and a low Price-to-Sales ratio compared to historical averages. Insider and guru activity also show a cautious stance, with net selling and position trimming observed.

Full Transcript: Regenxbio Q2 2026 Earnings Call

https://www.benzinga.com/news/26/10/62157013/full-transcript-regenxbio-q2-2026-earnings-call
Regenxbio reported strong Q2 2026 financial results and significant progress in its gene therapy pipeline, including completing enrollment for RGX202's confirmatory study and receiving a $100 million milestone payment from AbbVie. The company ended the quarter with over $310 million pro forma cash, extending its runway into Q4 2027 to support strategic priorities like the U.S. commercial launch preparation for RGX202 and global regulatory submissions. Management expressed confidence in future product launches and transformative therapies, aiming for a BLA submission for RGX202 in Q3 2026 and continued development of Surivec for retinal diseases.

Mizuho initiates Regenxbio stock coverage with outperform rating By Investing.com

https://za.investing.com/news/stock-market-news/mizuho-initiates-regenxbio-stock-coverage-with-outperform-rating-93CH-4489407
Mizuho initiated coverage on Regenxbio Inc. (NASDAQ:RGNX) with an outperform rating and a price target of $22.00, citing the company’s gene therapy-based candidates for diseases with high unmet needs. The firm's model focuses on two lead assets: RGX-202 for Duchenne muscular dystrophy, with a U.S. regulatory filing expected in Q1 2027, and ABBV-RGX-314 for wet age-related macular degeneration and diabetic retinopathy, with top-line Phase 3 data expected this quarter. Despite recent challenges like a clinical hold on RGX-121, analyst firms like H.C. Wainwright and Stifel have reiterated Buy ratings, reflecting confidence in Regenxbio's pipeline and recent positive three-year data from its ALTITUDE study.
Advertisement

Mizuho initiates Regenxbio stock coverage with outperform rating By Investing.com

https://ca.investing.com/news/stock-market-news/mizuho-initiates-regenxbio-stock-coverage-with-outperform-rating-93CH-4865210
Mizuho has initiated coverage on Regenxbio Inc. (NASDAQ:RGNX) with an outperform rating and a price target of $22.00, representing a significant upside from its current price. The firm's positive outlook is based on Regenxbio's gene therapy pipeline, particularly RGX-202 for Duchenne muscular dystrophy and ABBV-RGX-314 for macular degeneration and diabetic retinopathy. Despite recent challenges like a clinical hold on another gene therapy (RGX-121), other analysts have reiterated "Buy" ratings, and an insider recently purchased over 102,000 shares, indicating confidence.

REGENXBIO stock reports durable gene therapy data from Phase II

https://www.ad-hoc-news.de/boerse/news/corporate-news/regenxbio-stock-reports-durable-gene-therapy-data-from-phase-ii/70224113
REGENXBIO reported durable three-year data from its Phase II ALTITUDE study for diabetic retinopathy, showing a 60% response rate in Dose Level 3 participants. The company also surpassed Q2 revenue and EPS expectations, though analysts still forecast a full-year loss. Despite a "Moderate Buy" consensus and a significantly higher average price target, the stock remains well below its 52-week high.

(RGNX) Price Dynamics and Execution-Aware Positioning

https://news.stocktradersdaily.com/news_release/81/RGNX_Price_Dynamics_and_Execution-Aware_Positioning_100326042402_1791059042.html
The article analyzes Regenxbio Inc. (NASDAQ: RGNX) stock dynamics, noting strong near-term sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and presents an exceptional short setup with a significant risk-reward ratio. The analysis, generated by AI models, provides institutional trading strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.

Net income before discontinued operations of REGENXBIO, Inc. – HAN:RB0

https://www.tradingview.com/symbols/HAN-RB0/financials-income-statement/net-income-bef-disc-oper/
This article provides financial data for REGENXBIO, Inc. (RB0) on the Hannover Stock Exchange, specifically focusing on its net income before discontinued operations. It indicates the market is currently closed with no trades, and the content is a data point provided by FactSet.

ETFs Investing in REGENXBIO, Inc. Stocks

https://www.tradingview.com/symbols/HAN-RB0/etfs/
This article lists various Exchange Traded Funds (ETFs) that hold REGENXBIO, Inc. (RB0) stocks. The list provides detailed information for each ETF, including market value, weight of RB0 in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return. It serves as a resource for investors interested in REGENXBIO, Inc. through diversified ETF portfolios.
Advertisement

H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $21

https://www.moomoo.com/news/post/1000297382/hc-wainwright-maintains-regenxbio-rgnxus-with-buy-rating-maintains-target
H.C. Wainwright has reiterated its Buy rating for Regenxbio (RGNX.US), maintaining a target price of $21. This indicates continued confidence from the analyst firm in the company's stock performance and future prospects.

Weekly Recap: REGENXBIO and UPenn settlement and $39M payment to Regenxbio

https://www.tradingview.com/news/tradingview:4c8e78b7dd161:0-weekly-recap-regenxbio-and-upenn-settlement-and-39m-payment-to-regenxbio/
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) settled patent suits with REGENXBIO and UPenn by paying $39 million. This settlement secures releases and AAVrh74/ELEVIDYS covenants, dismisses litigation, and ensures Sarepta's freedom to operate. Sarepta will also present new efficacy and safety data for ELEVIDYS at upcoming medical conferences.

REGENXBIO reports three-year ALTITUDE DRSS data

https://mugglehead.com/regenxbio-altitude-three-year-retinopathy-data/
REGENXBIO Inc. reported new three-year follow-up data from its ALTITUDE trial, showing that six out of ten higher-dose participants experienced a significant improvement in diabetic retinopathy severity. This data supports the ongoing Phase IIb/III NAAVIGATE trial, which is testing the gene therapy sura-vec against a sham control. The company expects topline results from its ATMOSPHERE and ASCENT trials for wet age-related macular degeneration in Q4 2026 and projects a cash runway into Q4 2027.

REGENXBIO reports three-year sura-vec Phase II results

https://grafa.com/en/news/united-states/regenxbio-sura-vec-phase-2-altitude-diabetic-retinopathy-results
REGENXBIO (NASDAQ:RGNX) announced positive three-year Phase II results from its ALTITUDE clinical trial for investigational gene therapy sura-vec in non-proliferative diabetic retinopathy. The data showed that 60% of participants, at the highest dose, achieved a significant improvement in diabetic retinopathy severity without further treatment and with no new safety signals or intraocular inflammation observed. This suggests sura-vec could be a promising single-administration treatment for NPDR.

REGENXBIO and Sarepta Resolve ELEVIDYS Patent Litigation with $39 Million Settlement

https://kalkinemedia.com/us/news/announcements/regenxbio-and-sarepta-resolve-elevidys-patent-litigation-with-39-million-settlement
REGENXBIO Inc. and Sarepta Therapeutics, along with Catalent, Inc. and the University of Pennsylvania, have settled their patent infringement litigation concerning the gene therapy product ELEVIDYS. Sarepta will pay REGENXBIO $39.0 million, and all related patent infringement claims regarding specific patents will be terminated. The agreement also includes a covenant not to sue Sarepta for future claims related to AAVrh74-based capsid gene therapy products, including ELEVIDYS, under the specified patents.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement